Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

• Jordan Amdahl,

  Affiliation Research, Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States of America

  ⨯
• Jose Diaz,

  Current address: Worldwide Health Economics and Outcomes Research Markets, Bristol-Myers Squibb, Twickenham, Greater London, United Kingdom

  Affiliation Global Health Outcomes − Oncology, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, United Kingdom

  ⨯
• Arati Sharma,

  Affiliation Research, Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States of America

  ⨯
• Jinhee Park,

  Affiliation Worldwide Health Outcomes, Value & Access, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• David Chandiwana,

  Affiliation Worldwide Health Outcomes, Value & Access, Novartis Pharmaceuticals UK Limited, Camberley, Surrey, United Kingdom

  ⨯
• Thomas E. Delea

  * E-mail: tdelea@pai2.com

  Affiliation Research, Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States of America

  http://orcid.org/0000-0001-5493-1925

  ⨯